MarketCap
Facebook
X
TelegramQuarterly report 2022-Q3
added 11-14-2022
Akouos EPS Ratio 2011-2026 | AKUS
EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.
The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]
EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.
A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.
EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.
Annual EPS Ratio Akouos
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.52 | -2.77 | -42.5 | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -2.52 | -42.5 | -15.9 |
Quarterly EPS Ratio Akouos
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | -0.54 | -0.58 | -0.78 | - | -0.67 | -0.66 | -0.47 | - | -0.85 | -11.1 | -14.7 | - | -13.2 | -3.42 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -0.47 | -14.7 | -4.28 |
References
- Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.
EPS Ratio of other stocks in the Biotechnology industry
| Issuer | EPS Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-15.4 | - | 2.43 % | $ 254 M |  Germany |
 |
Acer Therapeutics
ACER
|
-1.66 | - | 2.71 % | $ 14 M |  USA |
 |
AbbVie
ABBV
|
1.02 | $ 232.08 | 3.29 % | $ 411 B | USA |
 |
AbCellera Biologics
ABCL
|
-0.49 | $ 3.61 | 0.56 % | $ 1.08 B |  Canada |
 |
Abeona Therapeutics
ABEO
|
-2.53 | $ 5.12 | -1.54 % | $ 109 M | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
-0.44 | $ 4.66 | -0.85 % | $ 773 M | Canada |
 |
ACADIA Pharmaceuticals
ACAD
|
1.37 | $ 24.56 | -0.32 % | $ 4.07 B | USA |
 |
I-Mab
IMAB
|
-7.66 | - | - | $ 866 M |  China |
 |
Achieve Life Sciences
ACHV
|
-1.5 | $ 4.56 | -3.59 % | $ 90.4 M | USA |
 |
AC Immune SA
ACIU
|
-0.97 | $ 2.93 | -1.01 % | $ 229 M |  Schweiz |
 |
AgeX Therapeutics
AGE
|
-13.7 | - | -10.17 % | $ 12.2 K | USA |
 |
Aclaris Therapeutics
ACRS
|
-0.53 | $ 2.87 | -8.31 % | $ 352 M | USA |
 |
Biophytis SA
BPTS
|
-0.26 | - | -13.47 % | $ 169 M |  France |
 |
Aeglea BioTherapeutics
AGLE
|
-24.9 | - | - | $ 1.01 B | USA |
 |
Adagene
ADAG
|
-0.59 | $ 2.96 | -4.67 % | $ 167 M | China |
 |
ADC Therapeutics SA
ADCT
|
-3.77 | $ 4.1 | -0.73 % | $ 105 M | Schweiz |
 |
Adial Pharmaceuticals
ADIL
|
-2.72 | $ 2.53 | - | $ 16.4 M | USA |
 |
ADMA Biologics
ADMA
|
0.62 | $ 15.57 | 2.57 % | $ 3.71 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-0.36 | - | - | $ 26.5 M | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
-0.39 | $ 16.02 | -2.67 % | $ 2.43 B | USA |
 |
ADiTx Therapeutics
ADTX
|
-3.06 K | $ 0.46 | -4.63 % | $ 6.06 K | USA |
 |
Midatech Pharma plc
MTP
|
-31 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Agenus
AGEN
|
-0.69 | $ 3.33 | -0.89 % | $ 1.19 M | USA |
 |
Agios Pharmaceuticals
AGIO
|
-7.12 | $ 30.23 | 0.83 % | $ 1.75 B | USA |
 |
AIM ImmunoTech
AIM
|
-0.4 | $ 0.91 | -8.59 % | $ 43.8 M | USA |
 |
Akebia Therapeutics
AKBA
|
-0.02 | $ 1.31 | -0.76 % | $ 337 M | USA |
 |
Akari Therapeutics, Plc
AKTX
|
-0.09 | $ 0.24 | -8.87 % | $ 5.73 B | Britain |
 |
ARCA biopharma
ABIO
|
-3.87 | - | 1052.0 % | $ 415 M | USA |
 |
Acorda Therapeutics
ACOR
|
-204 | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
-0.79 | - | 4.01 % | $ 150 M | Canada |
 |
Aldeyra Therapeutics
ALDX
|
-0.56 | $ 5.46 | -0.73 % | $ 328 M | USA |
 |
Alector
ALEC
|
-1.39 | $ 2.43 | -5.08 % | $ 250 M | USA |
 |
Aligos Therapeutics
ALGS
|
-1.36 | $ 7.03 | -6.27 % | $ 452 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-6.62 | - | - | $ 86.2 M | USA |
 |
Alkermes plc
ALKS
|
1.47 | $ 30.1 | -2.05 % | $ 4.96 B |  Irlanda |
 |
Allogene Therapeutics
ALLO
|
-2.09 | $ 2.78 | 1.83 % | $ 436 M | USA |
 |
AIkido Pharma
AIKI
|
-2.38 | - | 1.93 % | $ 17.4 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
2.39 | $ 332.92 | 0.51 % | $ 43.6 B | USA |
 |
Akero Therapeutics
AKRO
|
-3.75 | - | - | $ 3.67 B | USA |
 |
Altimmune
ALT
|
-1.34 | $ 4.31 | -3.36 % | $ 306 M | USA |
 |
Albireo Pharma
ALBO
|
-1.77 | - | -0.23 % | $ 916 M | USA |
 |
ALX Oncology Holdings
ALXO
|
-2.58 | $ 2.11 | -10.21 % | $ 110 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-0.72 | - | 3.16 % | $ 1.9 M | USA |
 |
Amgen
AMGN
|
14.3 | $ 388.16 | 2.33 % | $ 209 B | USA |
 |
Aileron Therapeutics
ALRN
|
-3.51 | - | 10.36 % | $ 9.8 M | USA |
 |
AlloVir
ALVR
|
-11.7 | - | 4.14 % | $ 49.1 M | USA |